Previous 10 | Next 10 |
home / stock / anpcy / anpcy news
ANGLE LAUNCHES PD-L1 TEST TO SUPPORT CANCER THERAPY STUDIES ANGLE's Portrait PD-L1 test uses CTCs harvested from the Parsortix system to investigate real-time patient PD-L1 status for clinical studies The test is designed for highly accurate, repeatable, and precise results for CTC PD-L...
Revenue recognised for 2023 expected to be up 120% at c. £2.2 million with sales secured in 2023 expected to be c. £3.3 million Revenue recognised for 2024 expected to treble compared to 2023 Cash runway extended into Q2 2025 GUILDFORD, SURREY / ACCESSWIRE / November 9, 20...
RESEARCH DEMONSTRATES POTENTIAL OF THE PARSORTIX SYSTEM TO SUPPORT POWERFUL CHARACTERISATION OF CTCS IN HEAD AND NECK CANCER 41 key biomarkers including the immune checkpoint proteins PD-L1, CTLA4 and CD39 successfully evaluated Providing key information which could support the developm...
PARSORTIX SYSTEM OUTPERFORMS CURRENT LABORATORY STANDARD FOR DISSEMINATED TUMOUR CELL HARVEST DTCs linked to cancer relapse even after prolonged remission DTCs harvested by the Parsortix system were 'abundant and viable' facilitating biomarker assessment GUILDFORD, SURREY / ACCESSWIRE...
PARSORTIX SYSTEM SHOWCASED AT 'ADVANCES IN CIRCULATING TUMOR CELLS' CONFERENCE Nine poster presentations utilising the Parsortix system in six cancer types all received positive feedback GUILDFORD, SURREY / ACCESSWIRE / September 29, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-lead...
Interim Results for the six months ended 30 June 2023 BUILDING COMMERCIAL MOMENTUM DELIVERS REVENUE GROWTH Cash runway extended into Q1 2025 GUILDFORD, SURREY / ACCESSWIRE / September 7, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative ...
LAUNCH OF PORTRAIT FLEX CIRCULATING TUMOR CELL ASSAY The Portrait Flex assay provides tailored analyses performed as a service by ANGLE's Onc-ADaPT™ laboratories GUILDFORD, SURREY / ACCESSWIRE / September 4, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy co...
Notice of Interim Results and Webcast GUILDFORD, SURREY / ACCESSWIRE / August 15, 2023 / ANGLE plc (AIM:AGL), (OTCQX:ANPCY), a world-leading liquid biopsy company with innovative CTC diagnostic solutions for the research and diagnostic oncology market, will be releasing its interim results f...
GUILDFORD, SURREY / ACCESSWIRE / June 28, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today, all resolutions were duly passed. For further information: Notes for editors About ANG...
GUILDFORD, SURREY / ACCESSWIRE / June 27, 2023 / TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN Issuer Name UK or Non-UK Issuer 2. Reason for Notification 3. Details of person subject to the notification obligation Name City of registered off...
News, Short Squeeze, Breakout and More Instantly...
Angle Plc Surrey ADR Company Name:
ANPCY Stock Symbol:
OTCMKTS Market:
Angle Plc Surrey ADR Website:
GUILDFORD, SURREY / ACCESSWIRE / July 11, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today, all resolutions were duly passed. For further information: Notes for editors About ANG...
GUILDFORD, SURREY / ACCESSWIRE / June 18, 2024 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that the audited Annual Report a...
PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT THE 2024 ANNUAL CONGRESS OF THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH ANGLE presenting two posters highlighting the utility of CTC & ctDNA dual analysis and ANGLE's DNA Damage Response assay GUILDFORD, SURREY / ACCESSWIRE / June 11, ...